Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ: ACAD )

20.04 +0.27 (+1.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Bear Market Bets In Biotech
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) and Stoke Therapeutics Inc (NASDAQ: STOK) will team up on the treatments in rare genetic neurodevelopmental diseases of... 
Via Benzinga
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
From Acadia Pharmaceuticals Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE: 
Via Benzinga
What 17 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ: 
Via Benzinga
$1000 Invested In This Stock 10 Years Ago, Would Be Worth This Much
ACADIA Pharmaceuticals (NASDAQ:ACAD) has outperformed the market over the past 10 years by 22.05% on an annualized basis. Buying $1,000 In ACAD: 10 years ago, an investor could... 
Via Benzinga
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST... 
Via Benzinga
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
55 Biggest Movers From Yesterday
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
What Analysts Have To Say On Acadia's Narrower Nuplazid Label Expansion Bid
RBC Capital 
Via Benzinga
Acadia Slims Nuplazid Label Expansion Application For Alzheimer's Disease Psychosis
After suffering rejection from the FDA in April, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is making another bid to expand the scope of its Parkinson's disease... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4... 
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining... 
Via Benzinga
Why This Acadia Pharmaceuticals Move Has Analysts Split — And Shares Down 20%
After a rejection in April, Acadia is planning to ask for approval in Alzheimer's patients. 
Via Investor's Business Daily
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD 
Via Benzinga
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Top Biotech Stocks: Trading Opportunities For Next Week
A security pattern traces the distinct movements of prices, which helps traders make informed trading decisions. Let's look at some biotech stock opportunities by analyzing these patterns. 
Via Talk Markets
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Over the past 3 months, 7 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ: 
Via Benzinga
Why Acadia Pharmaceuticals Stock Is Rocketing Today
A positive clinical readout is lighting a fire underneath the biotech's shares today. 
Via The Motley Fool
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 18.35% to $22.96 during Tuesday's pre-market session. The company's market cap stands at $3.6 billion.... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Oppenheimer cut the price target on Coupa Software Incorporated (NASDAQ: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! We're beginning another busy day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
22 Stocks Moving in Tuesday's Pre-Market Session
Gainers Bluejay Diagnostics, Inc. (NASDAQ: BJDX) rose 23.7% to $3.18 in pre-market trading after jumping 10% on Monday. The company, last month, priced its IPO at $10 per unit.... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Acadia Pharma Jumps After Rett Syndrome Candidate Aces Phase 3 Study
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from Phase 3 Lavender study of trofinetide in Rett syndrome. The 12-week study demonstrated a... 
Via Benzinga
Acadia Pharmaceuticals Stock Sprints After Rett Syndrome Drug Scores A Testing Win
The drug showed improvements across multiple measures of Rett syndrome. 
Via Investor's Business Daily
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.